UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

UPB UpStream Bio Inc.

休市中 08-21 16:00:00 EDT

6.97

+0.12

+1.75%

盘后6.84

-0.13-1.87%

19:30 EDT

最高7.01	最低6.85	成交量43.42万
今开6.91	昨收6.85	日振幅2.28%
总市值3.82亿	流通市值3.25亿	总股本5,477万
成交额301.97万	换手率0.93%	流通股本4,668万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":6.97,"timestamp":1787342400000,"preClose":6.85,"halted":0,"volume":434241,"hourTrading":{"tag":"盘后","latestPrice":6.84,"preClose":6.97,"latestTime":"19:30 EDT","volume":157,"amount":1079.2155,"timestamp":1787355007608,"change":-0.13,"changeRate":-0.018651,"amplitude":0.018651},"delay":0,"changeRate":0.017518248175182497,"floatShares":46680775,"shares":54771041,"eps":-2.875781,"marketStatus":"休市中","change":0.12,"latestTime":"08-21 16:00:00 EDT","open":6.91,"high":7.0062,"low":6.85,"amount":3019678.3471707,"amplitude":0.022803,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.875781,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":6.85,"preHourTrading":{"tag":"盘前","latestPrice":6.98,"preClose":6.85,"latestTime":"09:13 EDT","volume":201,"amount":1402.98,"timestamp":1787317997489,"change":0.13,"changeRate":0.018978,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":6.84,"preClose":6.97,"latestTime":"19:30 EDT","volume":157,"amount":1079.2155,"timestamp":1787355007608,"change":-0.13,"changeRate":-0.018651,"amplitude":0.018651},"volumeRatio":0.6850123912661289,"impliedVol":1.3476,"impliedVolPercentile":0.6056},"requestUrl":"/m/hq/s/UPB","defaultTab":"news","newsList":[{"id":"1117178706","title":"Upstream Bio在EAACI 2026大会上公布新应答者分析：Verekitug在二期VIBRANT试验中为绝大多数CRSwNP患者带来具临床意义的改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1117178706","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117178706?lang=zh_cn&edition=full","pubTime":"2026-06-14 22:00","pubTimestamp":1781445620,"startTime":"0","endTime":"0","summary":"Upstream Bio公司于2026年欧洲过敏与临床免疫学会大会上，公布了其候选药物Verekitug在二期VIBRANT试验中的最新应答者分析数据。结果显示，在接受Verekitug治疗的患者中，绝大多数患有慢性鼻窦炎伴鼻息肉的参与者，其病情获得了具有临床意义的显著改善。这项深入分析进一步证实了Verekitug作为一款潜在疗法的积极信号。此次在EAACI这一权威国际会议上展示的数据，增强了Verekitug在治疗CRSwNP这一领域的前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123552714","title":"上游生物将在EAACI 2026口头报告环节展示Verekitug针对CRSwNP的二期Vibrant试验额外疗效数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1123552714","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123552714?lang=zh_cn&edition=full","pubTime":"2026-06-08 19:00","pubTimestamp":1780916426,"startTime":"0","endTime":"0","summary":"上游生物公司计划在即将举行的欧洲过敏与临床免疫学会2026年大会上，通过口头报告形式，进一步公布其候选药物Verekitug用于治疗慢性鼻窦炎伴鼻息肉病的二期Vibrant临床试验的额外疗效数据。此次展示旨在向科学界提供关于该疗法潜力的更深入见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104582898","title":"Upstream Bio在ATS 2026国际会议上公布Verekitug二期Vibrant试验新数据，显示其改善CRSwNP合并哮喘患者的哮喘症状控制","url":"https://stock-news.laohu8.com/highlight/detail?id=1104582898","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104582898?lang=zh_cn&edition=full","pubTime":"2026-05-18 23:30","pubTimestamp":1779118224,"startTime":"0","endTime":"0","summary":"Upstream Bio在2026年美国胸科学会国际会议上，公布了其候选药物Verekitug在二期Vibrant临床试验中的最新数据。数据显示，对于同时患有慢性鼻窦炎伴鼻息肉和哮喘的患者，Verekitug在改善哮喘症状控制方面展现出积极效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162420003","title":"Upstream Bio公布Verekitug三期临床试验战略及2025年第四季度与全年财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1162420003","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162420003?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:03","pubTimestamp":1774523017,"startTime":"0","endTime":"0","summary":"生物制药公司Upstream Bio近日宣布了其核心候选药物Verekitug的三期临床开发战略，并同步披露了2025年第四季度及全年的财务报告。此次公布标志着Verekitug的研发进入关键阶段，公司对其未来市场前景充满信心。财务数据则反映了公司在研发投入与业务运营方面的最新状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618937974","title":"Upstream Bio, Inc.盘中异动 早盘股价大涨5.30%报8.55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618937974?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:40","pubTimestamp":1773236404,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日21时40分，Upstream Bio, Inc.股票出现异动，股价快速拉升5.30%。截至发稿，该股报8.55美元/股，成交量8.6864万股，换手率0.16%，振幅4.68%。Upstream Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.35%。Upstream Bio, Inc.公司简介：Upstream Bio Inc是一家临床阶段的生物技术公司，开发炎症性疾病的治疗方法，最初专注于严重的呼吸系统疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311214005a6b84de8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311214005a6b84de8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TSLP","BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134831765","title":"Upstream Bio在2026年AAAAI年会上公布Verekitug治疗慢性鼻窦炎伴鼻息肉的2期Vibrant试验补充分析结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1134831765","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134831765?lang=zh_cn&edition=full","pubTime":"2026-03-01 22:45","pubTimestamp":1772376313,"startTime":"0","endTime":"0","summary":"生物制药公司Upstream Bio于2026年美国过敏、哮喘与免疫学会（AAAAI）年会上，正式发布了其核心候选药物Verekitug在慢性鼻窦炎伴鼻息肉（CRSwNP）患者中开展的2期Vibrant临床试验的补充分析数据。此次公布的分析结果进一步揭示了Verekitug在这一适应症中的治疗潜力与作用机制，为后续临床开发提供了重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2486705257","title":"单月超6亿美元，医药企业IPO规模重返疫情前水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705257","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2486705257?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:34","pubTimestamp":1732527240,"startTime":"0","endTime":"0","summary":"今年以来，生物医药领域已经有30家公司IPO上市，累计融资规模超40.49亿美元，其中不乏CG Oncology、Kyverna Therapeutics等IPO规模超3亿美元的公司。在多肽类PTH1R激动剂领域，阿斯利康以总价18亿美元收购AmolytPharma，获得了处于临床3期的PTH1R激动剂eneboparatide，目前该疗法已经获得了FDA快速通道认定，另一家药企AscendisPharma的Yorvipath获得FDA批准上市，用于治疗成人慢性甲状旁腺功能减退。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-25/doc-incxhqmk8147031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SYRS","BK4561","PSQ","SQQQ","NQmain","BK4020","GPCR","AVTE","BK4007","CAMP","QLD","SEPN","BK4539","GLYC","MNQmain","ASO","TSLP","UPB","APGE","TQQQ","BDMD","BK4139","OMGA",".IXIC","QID","BK4200","BK4082","BK4599"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.upstreambio.com","stockEarnings":[{"period":"1week","weight":-0.0141},{"period":"1month","weight":0.0577},{"period":"3month","weight":-0.1673},{"period":"6month","weight":-0.1374},{"period":"1year","weight":-0.6071},{"period":"ytd","weight":-0.7433}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Upstream Bio, Inc.于2021年4月21日在特拉华州注册成立。他们是一家临床阶段的生物技术公司，开发炎症性疾病的治疗方法，最初专注于严重的呼吸系统疾病。他们正在开发verekitug，这是目前临床开发中唯一已知的拮抗剂，靶向胸腺间质淋巴细胞生成素（“TSLP”）受体，TSLP是一种细胞因子，是临床验证的炎症反应驱动因素，位于影响各种免疫介导疾病的多个信号级联的上游。迄今为止的临床前和临床数据表明，verekitug对TSLP受体具有高度有效的抑制作用，这将转化为差异化的产品特征，包括改善临床结果、大幅延长给药间隔和治疗广泛患者的潜力。","exchange":"NASDAQ","name":"UpStream Bio Inc.","nameEN":"UpStream Bio Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"UpStream Bio Inc.,UPB,UpStream Bio Inc.股票,UpStream Bio Inc.股票老虎,UpStream Bio Inc.股票老虎国际,UpStream Bio Inc.行情,UpStream Bio Inc.股票行情,UpStream Bio Inc.股价,UpStream Bio Inc.股市,UpStream Bio Inc.股票价格,UpStream Bio Inc.股票交易,UpStream Bio Inc.股票购买,UpStream Bio Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}